CORT · Corcept Therapeutics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $761.41M | $675.04M | $482.38M | $401.86M | $365.98M | $353.87M |
| Cost of Revenue | $12.98M | $10.88M | $6.48M | $5.38M | $5.28M | $5.58M |
| Gross Profit | $748.43M | $664.16M | $475.89M | $396.47M | $360.70M | $348.29M |
| R&D | $254.91M | $246.89M | $184.35M | $130.99M | $113.86M | $114.76M |
| SG&A | $448.73M | $280.32M | $184.26M | $152.85M | $122.36M | $105.33M |
| Total Operating Expenses | $716.61M | $538.09M | $375.09M | $289.22M | $241.50M | $225.67M |
| D&A | $1.15M | $795.0K | $577.0K | $782.0K | $1.07M | $525.0K |
| Operating Income | $44.80M | $136.95M | $107.28M | $112.63M | $124.48M | $128.20M |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | ($33.19M) | $20.28M | $18.42M | $14.77M | $12.49M | $25.59M |
| Net Income | $99.65M | $141.21M | $106.14M | $101.42M | $112.51M | $106.01M |
| EPS - Basic | $0.95 | $1.35 | $1.02 | $0.95 | $0.97 | $0.92 |
| EPS - Diluted | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $120.50M | $127.67M | $135.55M | $66.33M | $77.62M | $76.19M |
| Accounts Receivable | $59.79M | $53.98M | $41.12M | $31.06M | $27.63M | $26.20M |
| Inventory | $12.87M | $12.41M | $7.73M | $6.10M | $4.99M | $4.91M |
| Accounts Payable | $40.44M | $15.38M | $17.40M | $11.98M | $6.91M | $10.55M |
| Current Assets | $485.46M | $471.60M | $458.64M | $499.25M | $266.46M | $478.50M |
| Total Assets | $836.65M | $840.55M | $621.52M | $583.43M | $423.76M | $571.73M |
| Current Liabilities | $166.09M | $140.77M | $104.50M | $72.49M | $47.54M | $47.49M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $188.85M | $160.96M | $114.81M | $81.59M | $47.95M | $48.39M |
| Stockholders' Equity | $647.80M | $679.59M | $506.70M | $501.84M | $375.81M | $523.34M |
| Retained Earnings | $643.39M | $543.74M | $402.53M | $296.39M | $194.97M | $82.46M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $142.00M | $198.07M | $127.04M | $120.32M | $167.89M | $151.97M |
| Investing Cash Flow | $69.76M | ($177.60M) | $90.91M | ($114.33M) | $136.13M | ($119.26M) |
| Financing Cash Flow | ($220.37M) | ($28.35M) | ($148.72M) | ($17.28M) | ($302.59M) | $12.21M |
| CapEx | $211.0K | $2.17M | $139.0K | $413.0K | $469.0K | $1.24M |
| Free Cash Flow | $141.78M | $195.90M | $126.90M | $119.91M | $167.42M | $150.73M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% |
| Operating margin | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% |
| EBITDA margin | 6.0% | 20.4% | 22.4% | 28.2% | 34.3% | 36.4% |
| Net margin | 13.1% | 20.9% | 22.0% | 25.2% | 30.7% | 30.0% |
| Free cash flow margin | 18.6% | 29.0% | 26.3% | 29.8% | 45.7% | 42.6% |
| FCF / Net income | 1.42 | 1.39 | 1.20 | 1.18 | 1.49 | 1.42 |
| R&D / Revenue | 33.5% | 36.6% | 38.2% | 32.6% | 31.1% | 32.4% |
| SG&A / Revenue | 58.9% | 41.5% | 38.2% | 38.0% | 33.4% | 29.8% |
| Effective tax rate | -49.9% | 12.6% | 14.8% | 12.7% | 10.0% | 19.4% |
| Return on assets | 11.9% | 16.8% | 17.1% | 17.4% | 26.6% | 18.5% |
| Return on equity | 15.4% | 20.8% | 20.9% | 20.2% | 29.9% | 20.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.92 | 3.35 | 4.39 | 6.89 | 5.60 | 10.07 |
| Quick ratio | 2.85 | 3.26 | 4.31 | 6.80 | 5.50 | 9.97 |
| Cash ratio | 0.73 | 0.91 | 1.30 | 0.91 | 1.63 | 1.60 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.29 | 1.24 | 1.23 | 1.16 | 1.13 | 1.09 |
| Liabilities / Assets | 0.23 | 0.19 | 0.18 | 0.14 | 0.11 | 0.08 |
| Efficiency | ||||||
| Asset turnover | 0.91 | 0.80 | 0.78 | 0.69 | 0.86 | 0.62 |
| Inventory turnover | 1.01 | 0.88 | 0.84 | 0.88 | 1.06 | 1.14 |
| Days sales outstanding | 29d | 29d | 31d | 28d | 28d | 27d |
| Days inventory outstanding | 362d | 416d | 435d | 413d | 345d | 321d |
| Days payable outstanding | 1138d | 516d | 980d | 812d | 477d | 690d |
| Cash conversion cycle | -747d | -70d | -513d | -370d | -105d | -342d |
| Valuation | ||||||
| P / E | 42.4x | 41.0x | 34.6x | 23.3x | 22.2x | 30.8x |
| P / B | 6.4x | 8.4x | 7.2x | 4.7x | 6.6x | 6.2x |
| P / S | 5.5x | 8.5x | 7.5x | 5.9x | 6.8x | 9.2x |
| EV / EBITDA | 88.3x | 40.6x | 32.4x | 20.2x | 19.2x | 24.6x |
| Growth | ||||||
| Revenue growth (YoY) | 12.8% | 39.9% | 20.0% | 9.8% | 3.4% | 15.5% |
| Revenue CAGR (3y) | 23.7% | 22.6% | 10.9% | 9.5% | 65.1% | - |
| Revenue CAGR (5y) | 16.6% | 17.1% | 42.8% | - | - | - |
| Gross profit growth (YoY) | 12.7% | 39.6% | 20.0% | 9.9% | 3.6% | 15.7% |
| Operating income growth (YoY) | -67.3% | 27.7% | -4.8% | -9.5% | -2.9% | 14.9% |
| Net income growth (YoY) | -29.4% | 33.0% | 4.7% | -9.9% | 6.1% | 12.6% |
| EPS growth (YoY) | -33.3% | 30.9% | 8.0% | -2.2% | 4.7% | 10.4% |
| EPS CAGR (3y) | -2.0% | 11.4% | 3.4% | 4.2% | 14.0% | 129.8% |
| EPS CAGR (5y) | -0.7% | 9.8% | 9.4% | 65.5% | - | - |
| FCF growth (YoY) | -27.6% | 54.4% | 5.8% | -28.4% | 11.1% | 11.6% |
| FCF CAGR (5y) | -1.2% | 7.7% | 47.6% | 14.7% | 55.9% | 117.3% |
| Book value growth (YoY) | -4.7% | 34.1% | 1.0% | 33.5% | -28.2% | 41.0% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
3.44
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CORCEPT THERAPEUTICS INC against the 5 most active filers in the same SIC group.